Got this from WebMd, then googled Nitric Oxide from site Nitric Oxide Investigated as COVID-19 Treatment
By Robert Preidt
HealthDay Reporter
THURSDAY, April 9, 2020 (HealthDay News) -- Doctors at the University of Alabama at Birmingham (UAB) are enrolling patients in an international clinical trial to find out if inhaled nitric oxide benefits those with COVID-19 who have severely damaged lungs.
Right now, there are no approved treatments for the illness caused by the new coronavirus. A severe form of lung failure called acute respiratory distress syndrome is the leading cause of death in COVID-19.
When lungs are failing, air is received by some parts of them but not others. Nitric oxide is a gas that improves blood flow in areas of the lungs that are getting air, increasing the amount of oxygen in the blood stream.
Nitric oxide also reduces the workload of the right side of the heart, which is under extreme stress during lung failure.
Along with being used to treat failing lungs, nitric oxide has been found to have antiviral properties against coronaviruses. That was shown during the 2002-2003 SARS outbreak, which was caused by a coronavirus similar to the one that causes COVID-19.
Any COVID-19 patient in UAB's intensive care unit who is using a ventilator to breathe may qualify for the study.
"This trial will allow the sickest COVID-19 patients at UAB access to a rescue therapy that may have antiviral benefits in addition to improving the status of lungs," Dr. Vibhu Parcha said in a university news release. He's a research fellow in the Division of Cardiovascular Disease.
"In humans, nitric oxide is generated within the blood vessels and regulates blood pressure, and prevents the formation of clots and also destroys potential toxins," said Dr. Pankaj Arora, an assistant professor of cardiovascular disease. His team plans to study the cardiovascular effects of high-dose inhaled nitric oxide as part of the primary clinical trial.
So Nitric Oxide is being talked about on webmd.com, word is definately getting around those are really good things for this stock. Were going to the moon Alice and here is another reason as to why:
“R-107 is a liquid prodrug of nitric oxide that can be administered by injection, unlike nitric oxide gas, which requires a special type of delivery device, and complex administration by trained respiratory therapists. When administered by injection, R-107 is slowly hydrolyzed, releasing its active moiety, R-100, which in turn steadily and slowly releases nitric oxide into the lung tissue. This depot-like action of R-107 results in a sustained delivery of nitric oxide, allowing for a smooth delivery of the active drug over several days following a single dose of R-107."
Some paid basherlosers were talking about delisting, blah blah? I don’t think so. Win, win, sure to grin…
"Kalytera plans to submit an investigational new drug application to the Australian Therapeutic Goods Administration (TGA) and the U.S. Food and Drug Administration (FDA) for a clinical study of R-107 in patients with COVID-19-associated pneumonia and to initiate the trial immediately following clearance by these regulatory bodies." My guess this is going to happen sooner than later. Hello Alice, have you seen Penny or is that just a distant thought? lol GLTA